Figure 2From: Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents Adjusted mean (±95% CI) standardized 24 hour trough FEV 1 for indacaterol 150, 300 and 600 μg compared with placebo and formoterol 12 μg. ANCOVA for treatment contrasts: **p < 0.001 vs. placebo; †p < 0.01 and ‡p < 0.05 vs. formoterol; ¶p < 0.05 vs. indacaterol 150 μgBack to article page